After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
ORGO belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Organogenesis Holdings Inc is $622.87M. A total of 0.59 million shares were traded on the day, compared to an average of 940.06K shares.
In the most recent transaction, Freedman Lori bought 142,379 shares of ORGO for 2.91 per share on Jun 05 ’25. After the transaction, the Chief Admin. and Legal Officer now owns 837,437 company shares. In a previous transaction on Jun 04 ’25, Freedman Lori bought 100,863 shares at 2.82 per share. ORGO shares that Chief Admin. and Legal Officer owns now total 695,058.
Among the insiders who bought shares, Freedman Lori acquired of 9,022 shares on Jun 06 ’25 at a per-share price of $2.99. This resulted in the Chief Admin. and Legal Officer holding 846,459 shares of ORGO after the transaction. In another insider transaction, Driscoll Michael Joseph bought 25,000 shares at $5.08 per share on Mar 04 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ORGO has a high of $6.71 and a low of $2.43.
As of this writing, ORGO has an earnings estimate of $0.07 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of $0.07 per share and a lower estimate of $0.07. The company reported an EPS of $0.1 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ORGO’s latest balance sheet shows that the firm has $113.93M in Cash & Short Term Investments as of fiscal 2021. There were $132.30M in debt and $82.70M in liabilities at the time. Its Book Value Per Share was $1.84, while its Total Shareholder’s Equity was $241.34M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ORGO is Buy with a score of 5.00.
